# Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

> **NCT02445248** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 115 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma (DLBCL)

## Interventions

- **BIOLOGICAL:** Tisagenlecleucel
- **DRUG:** Lymphodepleting chemotherapy

## Key facts

- **NCT ID:** NCT02445248
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-29
- **Primary completion:** 2022-12-22
- **Final completion:** 2022-12-22
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02445248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02445248, "Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02445248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*